Fecal Calprotectin and Treatment Strategies in Ulcerative Colitis
Keywords:
Ulcerative colitis, calprotectin, inflammatory bowel disease, azathioprineAbstract
Ulcerative colitis (UC) is a long-term inflammatory condition that causes the intestinal mucosa to become inflamed over and over again. To treat it, you need a planned and goal-oriented approach. The major goal of therapy is to achieve long-term steroid-free remission while lowering the adverse effects and problems that come with treatment and the condition. Topical and oral 5-aminosalicylic acid (5-ASA) formulations are used for mild cases, whereas systemic corticosteroids, immunomodulators, and biologic therapies are utilized for moderate to severe cases. Consequently, these treatment strategies are dictated by the severity, scope, and clinical trajectory of the disease. Patients with refractory illness may need advanced therapies, such as calcineurin inhibitors (like cyclosporine or tacrolimus) or biologic medications (like infliximab), which are antibodies that fight tumor necrosis factor-alpha. Surgery is still needed for problems like toxic megacolon, perforation, or severe refractory hemorrhage. To get the best outcomes from this kind of treatment, intestinal inflammation has to be precisely measured. Faecal calprotectin has emerged as a reliable, non-invasive biomarker for intestinal inflammation in recent years. It is very useful in medicine for keeping track of illnesses, predicting relapses, and evaluating how well treatments are working. Integrating it into clinical practice allows for quick changes to treatment and better disease activity evaluation. Including fecal calprotectin in clinical decision-making makes it feasible to have a more personalized and proactive treatment plan. This makes it possible to use faecal calprotectin-guided approaches that cut down on the necessity for invasive procedures like colonoscopy. Because of this, faecal calprotectin is very important for better managing UC, improving the results of the disease, and making treatment decisions that follow approved global standards.
References
1. asvol TJ, Horsfall L, Bloom S, et al. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020;10:e036584.
2. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut. 2019;68:1953–1960.
3. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.
4. Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem. 2018;87:161–190.
5. Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2025;120(6):1225–1264.
6. Kapel N, Ouni H, Benahmed NA, Barbot-Trystram L. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. Clin Transl Gastroenterol. 2023;14(9):e00617. doi:10.14309/ctg.0000000000000617.
7. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68 Suppl 1:s1–s106.
8. Shah SC, Itzkowitz SH. Reappraising risk factors for inflammatory bowel disease-associated neoplasia: implications for colonoscopic surveillance in IBD. J Crohns Colitis. 2020;14:1172–1177.
9. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
10. Le Berre C, Peyrin-Biroulet L, SPIRIT-IOIBD study group. Selecting endpoints for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology. 2021;S0016-5085(21)00016-0.
11. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–2224. doi:10.1002/ibd.22917.
12. Ma R, Meng R, Zhang X, Sun Z, Lei Y. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med. 2020;20:1498–1504.
13. Steinsbø Ø, Aasprong OG, Aabakken L, Karlsen LN, Grimstad T. Fecal calprotectin correlates with disease extent but remains a reliable marker of mucosal healing in ulcerative colitis. Am J Gastroenterol. 2025;120(11):2623–2631. doi:10.14309/ajg.0000000000003339.
14. Sonoyama H, Kawashima K, Ishihara S, et al. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr. 2019.
15. Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987–995.
16. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617–2625.
17. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123–131.
18. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
19. Loftus EV, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1353–1365.
20. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
21. Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215–1226.
22. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.
23. Kawashima K, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 2016;16(1):47.
24. Sandborn WJ, Sands BE, Panaccione R, et al. OP37 efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. J Crohns Colitis. 2019;13 Suppl 1:S025–S026.
25. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
26. Sandborn WJ, Panés J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019;50:1068.
27. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.
28. Danese S. New drugs in the ulcerative colitis pipeline: prometheus unbound. Gastroenterology. 2020;158:467–470.
29. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104(3):673–678.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
